Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency

Franco Lori, Richard B Pollard, L. Whitman, N. Bakare, G. Blick, P. Shalit, A. Foli, D. Peterson, A. Tennenberg, S. Schrader, B. Rashbaum, C. Farthing, D. Herman, D. Norris, P. Greiger, I. Frank, A. Groff, L. Lova, David Asmuth, J. Lisziewicz

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination. In a randomized, open-label study (RIGHT 702, a multicenter trial performed in private and institutional practices), three daily doses (600 μg, 800-900 μg, and 1200 μg) of hydroxyurea were administered in combination with didanosine and stavudine to 115 chronically HIV-infected patients, one-third antiretroviral drug naive, with viremia between 5000 and 200,000 copies/ml regardless of CD4+ cell count. The primary efficacy end point was the proportion of patients with plasma HIV-1 RNA levels below 400 copies/ml after 24 weeks of therapy. In the RIGHT 702 intent-to-treat population the lowest (600 mg) dose of hydroxyurea was better tolerated, associated with fewer adverse events, and more potent by all efficacy parameters, including the primary end point (76 versus 60% patients with viremia < 400 copies/ml at week 24 for the 600-mg and 800- to 900-mg dose groups, respectively; p = 0.027), the mean area under the curve (60.3 versus 65.8; p = 0.016), and the mean log10 decrease (-1.95 versus -0.77; p = 0.001). Patients receiving 600 mg of hydroxyurea daily also had the highest CD4+ cell count, CD4+/CD8+ cell ratio, and lowest CD8+ cell count and percentage (p = 0.035). The RIGHT 702 trial provides an explanation for the increased toxicity and decreased efficacy of hydroxyurea when it was used at high dosage (1200 mg daily). At the optimal dosage of 600 mg daily, hydroxyurea, in combination with didanosine, deserves reevaluation for the long-term management of HIV/AIDS worldwide, because of its excellent resistance profile, durability, and affordability.

Original languageEnglish (US)
Pages (from-to)263-272
Number of pages10
JournalAIDS Research and Human Retroviruses
Volume21
Issue number4
DOIs
StatePublished - Apr 2005
Externally publishedYes

Fingerprint

Hydroxyurea
HIV
Didanosine
Viremia
CD4 Lymphocyte Count
Institutional Practice
Stavudine
CD4-CD8 Ratio
Private Practice
Multicenter Studies
Area Under Curve
Antiviral Agents
HIV-1
Acquired Immunodeficiency Syndrome
Cell Count
RNA
Pharmaceutical Preparations
Population

ASJC Scopus subject areas

  • Immunology
  • Virology

Cite this

Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. / Lori, Franco; Pollard, Richard B; Whitman, L.; Bakare, N.; Blick, G.; Shalit, P.; Foli, A.; Peterson, D.; Tennenberg, A.; Schrader, S.; Rashbaum, B.; Farthing, C.; Herman, D.; Norris, D.; Greiger, P.; Frank, I.; Groff, A.; Lova, L.; Asmuth, David; Lisziewicz, J.

In: AIDS Research and Human Retroviruses, Vol. 21, No. 4, 04.2005, p. 263-272.

Research output: Contribution to journalArticle

Lori, F, Pollard, RB, Whitman, L, Bakare, N, Blick, G, Shalit, P, Foli, A, Peterson, D, Tennenberg, A, Schrader, S, Rashbaum, B, Farthing, C, Herman, D, Norris, D, Greiger, P, Frank, I, Groff, A, Lova, L, Asmuth, D & Lisziewicz, J 2005, 'Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency', AIDS Research and Human Retroviruses, vol. 21, no. 4, pp. 263-272. https://doi.org/10.1089/aid.2005.21.263
Lori, Franco ; Pollard, Richard B ; Whitman, L. ; Bakare, N. ; Blick, G. ; Shalit, P. ; Foli, A. ; Peterson, D. ; Tennenberg, A. ; Schrader, S. ; Rashbaum, B. ; Farthing, C. ; Herman, D. ; Norris, D. ; Greiger, P. ; Frank, I. ; Groff, A. ; Lova, L. ; Asmuth, David ; Lisziewicz, J. / Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency. In: AIDS Research and Human Retroviruses. 2005 ; Vol. 21, No. 4. pp. 263-272.
@article{e6d19d50d03f44439542d25ada0c2b1f,
title = "Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency",
abstract = "The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination. In a randomized, open-label study (RIGHT 702, a multicenter trial performed in private and institutional practices), three daily doses (600 μg, 800-900 μg, and 1200 μg) of hydroxyurea were administered in combination with didanosine and stavudine to 115 chronically HIV-infected patients, one-third antiretroviral drug naive, with viremia between 5000 and 200,000 copies/ml regardless of CD4+ cell count. The primary efficacy end point was the proportion of patients with plasma HIV-1 RNA levels below 400 copies/ml after 24 weeks of therapy. In the RIGHT 702 intent-to-treat population the lowest (600 mg) dose of hydroxyurea was better tolerated, associated with fewer adverse events, and more potent by all efficacy parameters, including the primary end point (76 versus 60{\%} patients with viremia < 400 copies/ml at week 24 for the 600-mg and 800- to 900-mg dose groups, respectively; p = 0.027), the mean area under the curve (60.3 versus 65.8; p = 0.016), and the mean log10 decrease (-1.95 versus -0.77; p = 0.001). Patients receiving 600 mg of hydroxyurea daily also had the highest CD4+ cell count, CD4+/CD8+ cell ratio, and lowest CD8+ cell count and percentage (p = 0.035). The RIGHT 702 trial provides an explanation for the increased toxicity and decreased efficacy of hydroxyurea when it was used at high dosage (1200 mg daily). At the optimal dosage of 600 mg daily, hydroxyurea, in combination with didanosine, deserves reevaluation for the long-term management of HIV/AIDS worldwide, because of its excellent resistance profile, durability, and affordability.",
author = "Franco Lori and Pollard, {Richard B} and L. Whitman and N. Bakare and G. Blick and P. Shalit and A. Foli and D. Peterson and A. Tennenberg and S. Schrader and B. Rashbaum and C. Farthing and D. Herman and D. Norris and P. Greiger and I. Frank and A. Groff and L. Lova and David Asmuth and J. Lisziewicz",
year = "2005",
month = "4",
doi = "10.1089/aid.2005.21.263",
language = "English (US)",
volume = "21",
pages = "263--272",
journal = "AIDS Research and Human Retroviruses",
issn = "0889-2229",
publisher = "Mary Ann Liebert Inc.",
number = "4",

}

TY - JOUR

T1 - Lowering the dose of hydroxyurea minimizes toxicity and maximizes anti-HIV potency

AU - Lori, Franco

AU - Pollard, Richard B

AU - Whitman, L.

AU - Bakare, N.

AU - Blick, G.

AU - Shalit, P.

AU - Foli, A.

AU - Peterson, D.

AU - Tennenberg, A.

AU - Schrader, S.

AU - Rashbaum, B.

AU - Farthing, C.

AU - Herman, D.

AU - Norris, D.

AU - Greiger, P.

AU - Frank, I.

AU - Groff, A.

AU - Lova, L.

AU - Asmuth, David

AU - Lisziewicz, J.

PY - 2005/4

Y1 - 2005/4

N2 - The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination. In a randomized, open-label study (RIGHT 702, a multicenter trial performed in private and institutional practices), three daily doses (600 μg, 800-900 μg, and 1200 μg) of hydroxyurea were administered in combination with didanosine and stavudine to 115 chronically HIV-infected patients, one-third antiretroviral drug naive, with viremia between 5000 and 200,000 copies/ml regardless of CD4+ cell count. The primary efficacy end point was the proportion of patients with plasma HIV-1 RNA levels below 400 copies/ml after 24 weeks of therapy. In the RIGHT 702 intent-to-treat population the lowest (600 mg) dose of hydroxyurea was better tolerated, associated with fewer adverse events, and more potent by all efficacy parameters, including the primary end point (76 versus 60% patients with viremia < 400 copies/ml at week 24 for the 600-mg and 800- to 900-mg dose groups, respectively; p = 0.027), the mean area under the curve (60.3 versus 65.8; p = 0.016), and the mean log10 decrease (-1.95 versus -0.77; p = 0.001). Patients receiving 600 mg of hydroxyurea daily also had the highest CD4+ cell count, CD4+/CD8+ cell ratio, and lowest CD8+ cell count and percentage (p = 0.035). The RIGHT 702 trial provides an explanation for the increased toxicity and decreased efficacy of hydroxyurea when it was used at high dosage (1200 mg daily). At the optimal dosage of 600 mg daily, hydroxyurea, in combination with didanosine, deserves reevaluation for the long-term management of HIV/AIDS worldwide, because of its excellent resistance profile, durability, and affordability.

AB - The goal of this study was to optimize the hydroxyurea dosage in HIV-infected patients, and to minimize the toxicity and maximize the antiviral efficacy of the hydroxyurea-didanosine combination. In a randomized, open-label study (RIGHT 702, a multicenter trial performed in private and institutional practices), three daily doses (600 μg, 800-900 μg, and 1200 μg) of hydroxyurea were administered in combination with didanosine and stavudine to 115 chronically HIV-infected patients, one-third antiretroviral drug naive, with viremia between 5000 and 200,000 copies/ml regardless of CD4+ cell count. The primary efficacy end point was the proportion of patients with plasma HIV-1 RNA levels below 400 copies/ml after 24 weeks of therapy. In the RIGHT 702 intent-to-treat population the lowest (600 mg) dose of hydroxyurea was better tolerated, associated with fewer adverse events, and more potent by all efficacy parameters, including the primary end point (76 versus 60% patients with viremia < 400 copies/ml at week 24 for the 600-mg and 800- to 900-mg dose groups, respectively; p = 0.027), the mean area under the curve (60.3 versus 65.8; p = 0.016), and the mean log10 decrease (-1.95 versus -0.77; p = 0.001). Patients receiving 600 mg of hydroxyurea daily also had the highest CD4+ cell count, CD4+/CD8+ cell ratio, and lowest CD8+ cell count and percentage (p = 0.035). The RIGHT 702 trial provides an explanation for the increased toxicity and decreased efficacy of hydroxyurea when it was used at high dosage (1200 mg daily). At the optimal dosage of 600 mg daily, hydroxyurea, in combination with didanosine, deserves reevaluation for the long-term management of HIV/AIDS worldwide, because of its excellent resistance profile, durability, and affordability.

UR - http://www.scopus.com/inward/record.url?scp=20944432467&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20944432467&partnerID=8YFLogxK

U2 - 10.1089/aid.2005.21.263

DO - 10.1089/aid.2005.21.263

M3 - Article

C2 - 15943568

AN - SCOPUS:20944432467

VL - 21

SP - 263

EP - 272

JO - AIDS Research and Human Retroviruses

JF - AIDS Research and Human Retroviruses

SN - 0889-2229

IS - 4

ER -